GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Change In Payables And Accrued Expense

Meribank Biotech Co (ROCO:4724) Change In Payables And Accrued Expense : NT$0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co Change In Payables And Accrued Expense?

Meribank Biotech Co's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was NT$0.0 Mil. It means Meribank Biotech Co's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Meribank Biotech Co's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was NT$0.0 Mil. It means Meribank Biotech Co's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Meribank Biotech Co Change In Payables And Accrued Expense Historical Data

The historical data trend for Meribank Biotech Co's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co Change In Payables And Accrued Expense Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial - - - - -

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Meribank Biotech Co Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Meribank Biotech Co Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Meribank Biotech Co (ROCO:4724) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
ROCO:6564 ROCO:6580 TPE:1733 ROCO:7427 ROCO:4194 ROCO:6879 ROCO:4130 ROCO:6846 TPE:3164 ROCO:4168 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Website
http://www.meribank.com.tw
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines